Apeikon

Apeikon Therapeutics has developed Magnetic Resonance (MR) imaging and Focused Ultrasound (MRgFUS) targeted triggered treatments (3T technology) to address unmet clinical needs (e.g., hard to treat cancers).

The technology involves MRI traceable drug liposomes that provide the signal to focus thousands of ultrasound transducers onto a tumour.  This remotely activates the drug release into the tumour for optimum therapeutic effect. The technology also limits systemic drug exposure and minimises adverse effects.

3T is a platform technology suitable for old and new drugs, alone or in combinations. 3T technology is designed to deliver highly efficient and safe anticancer treatments.